Kailera Therapeutics (KLRA) investor relations material

Executive summary

• Advanced four clinical-stage GLP-1-based obesity programs, including five late-stage global trials and a lead asset in global Phase 3 trials.

• Reported positive topline data from three partner-conducted trials in China, including KAI-7535 and KAI-4729.

• Closed a $718.8 million IPO, providing capital to fund operations into mid-2028.

• Expanded leadership with key board appointments to support R&D and corporate development.

• No product revenue to date; operations funded by equity and convertible preferred stock.

Financial highlights

• Q1 2026 net loss: $78.9 million, up from $18.0 million in Q1 2025, driven by higher R&D and G&A expenses.

• Research and development expenses: $70.9 million (Q1 2026), up from $10.1 million (Q1 2025).

• General and administrative expenses: $13.8 million (Q1 2026), up from $10.3 million (Q1 2025).

• Cash, cash equivalents, and marketable securities: $581.9 million as of March 31, 2026.

• Accumulated deficit: $447.5 million as of March 31, 2026.

Outlook and guidance

• Cash on hand plus IPO proceeds expected to fund operations into mid-2028.

• U.S. Phase 2b high dose ribupatide injection data expected in 2027; global Phase 3 data in 2028.

• Ribupatide oral global Phase 3 trials to begin as early as 1H 2027.

• KAI-7535 global Phase 2 obesity data anticipated in 2027.

• KAI-4729 Phase 1 trial outside China to initiate by end of 2026, with data in 2027.